These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A phase 2 study of the bivalent VLP norovirus vaccine candidate in older adults; impact of MPL adjuvant or a second dose. Treanor J; Sherwood J; Cramer JP; Le Cam Bouveret N; Lin S; Baehner F; Borkowski A; Vaccine; 2020 Aug; 38(36):5842-5850. PubMed ID: 32563606 [TBL] [Abstract][Full Text] [Related]
5. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. Treanor JJ; Atmar RL; Frey SE; Gormley R; Chen WH; Ferreira J; Goodwin R; Borkowski A; Clemens R; Mendelman PM J Infect Dis; 2014 Dec; 210(11):1763-71. PubMed ID: 24951828 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a bivalent virus-like particle norovirus vaccine in children from 1 to 8 years of age: A phase 2 randomized, double-blind study. Vesikari T; Saez-Llorens X; Blazevic V; Lopez P; Lopez E; Masuda T; Mendelman PM; Liu M; Sherwood J; Baehner F; Borkowski A Vaccine; 2022 Jun; 40(26):3588-3596. PubMed ID: 35595661 [TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine. Leroux-Roels I; Maes C; Joye J; Jacobs B; Jarczowski F; Diessner A; Janssens Y; Waerlop G; Tamminen K; Heinimäki S; Blazevic V; Leroux-Roels G; Klimyuk V; Adachi H; Hiruta K; Thieme F Front Immunol; 2022; 13():1021500. PubMed ID: 36275772 [TBL] [Abstract][Full Text] [Related]
9. Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine. Sundararajan A; Sangster MY; Frey S; Atmar RL; Chen WH; Ferreira J; Bargatze R; Mendelman PM; Treanor JJ; Topham DJ Vaccine; 2015 Jan; 33(4):568-76. PubMed ID: 25444793 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial. López P; López-Medina E; Sáez-Llorens X; deAntonio R; Masuda T; Mendelman PM; Sherwood J; Baehner F; Borkowski A Hum Vaccin Immunother; 2023 Dec; 19(1):2204787. PubMed ID: 37140558 [TBL] [Abstract][Full Text] [Related]
11. Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse Sera. Malm M; Tamminen K; Vesikari T; Blazevic V Viral Immunol; 2018 Dec; 31(10):649-657. PubMed ID: 30431404 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of an intramuscular bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate in healthy US adults. Sherwood J; Mendelman PM; Lloyd E; Liu M; Boslego J; Borkowski A; Jackson A; Faix D; Vaccine; 2020 Sep; 38(41):6442-6449. PubMed ID: 32878708 [TBL] [Abstract][Full Text] [Related]
14. Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus Than Sequential Immunization. Malm M; Vesikari T; Blazevic V Viruses; 2019 Nov; 11(11):. PubMed ID: 31684058 [TBL] [Abstract][Full Text] [Related]
15. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial. Lindesmith LC; Ferris MT; Mullan CW; Ferreira J; Debbink K; Swanstrom J; Richardson C; Goodwin RR; Baehner F; Mendelman PM; Bargatze RF; Baric RS PLoS Med; 2015 Mar; 12(3):e1001807. PubMed ID: 25803642 [TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP; Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Parra GI; Bok K; Taylor R; Haynes JR; Sosnovtsev SV; Richardson C; Green KY Vaccine; 2012 May; 30(24):3580-6. PubMed ID: 22469864 [TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial. Kim L; Liebowitz D; Lin K; Kasparek K; Pasetti MF; Garg SJ; Gottlieb K; Trager G; Tucker SN JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997294 [TBL] [Abstract][Full Text] [Related]
19. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes. Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474 [TBL] [Abstract][Full Text] [Related]